Product Reach Lead with Vitaros, Apricus’s lead ED product approved in Europe and Canada with ongoing multi-country commercialization through established partners (Mylan, Takeda, Hexal, Recordati, Bracco, Lab Majorelle) to expand geographic footprint and drive near-term revenue.

Partner Opportunities Tap into existing distributor and co-marketing networks to accelerate market entry in additional European and international markets, leveraging current partnerships to scale access and reduce launch risk.

R&D Pipeline Leverage ongoing Phase 2b and Phase 2a programs (fispemifene for hypogonadism and RayVa for Raynaud’s) to create adjacent, cross-selling opportunities within urology and rheumatology portfolios, expanding consultative selling and trial collaboration discussions.

Strategic M&A Synergy The historical Seelos Therapeutics merger indicates readiness for strategic collaborations or acquisitions; position Apricus as a potential partner for in-licensing late-stage assets or co-development opportunities to broaden the product slate.

Financial & Market Potential With a modest revenue base and selective funding history, target performance-focused deals, CRO/clinical services partnerships, and regional licensing deals that align with current capital structure while accelerating utilization of Vitaros and advancing pipeline milestones.